e4life Devices Take Stage at Japan Health in Osaka from 25 th to 27 th June
ROME--(BUSINESS WIRE)--Can electromagnetic waves neutralize respiratory viruses? The answer is yes: on the stage of the Japan Health fair, from 25 th to 27 th June, e4life, the Italian company active in the biodefense industry, will be among the leading players presenting its innovative devices which use electromagnetic waves to render harmless respiratory viruses present in the air (transported via bioaerosol).
Vincenzo Pompa, e4life CEO: 'e4life marks a breakthrough for applications in high-risk environments, both human and animal, to minimize contagion among the animals themselves and also to reduce the risk of spillover".
Share
This solution is a world first, with efficacy of over 90% and an almost instantaneous sanitizing action. Since it is 100% harmless to humans and animals, it does not require the evacuation of spaces and environments.
This Italian patent does not use chemical agents or filter materials, and is based on the transmission of microwaves which, at a specific combination of frequency and power, act on the balance between the internal positive charges of the virus and the negative charges present in the capsid or outer shell, giving rise to a 'resonance' phenomenon that destroys the external envelope of the virus and effectively inhibits its power to spread and to infect.
The key intuitive moment came during the pandemic period and required two years of studies and in-depth analysis, starting from a research carried out by Taiwanese scientists published in the Nature Scientific Report. The first results came from testing different frequencies of electromagnetic waves on Covid and later, on other pathogens. One of the most interesting features of this new technology is the possibility of having a targeted action, allowing it to be calibrated on specific pathogens changing the resonance frequence.
Its effectiveness has been validated against Covid, including recent variants, RSV and seasonal flu (in this case the effectiveness exceeds 95%), Avian Flu and Swine Flu. e4life has an important roadmap of research focused on constantly evolving and adapting the devices to an ever-increasing number of viruses and, in the near future, also bacteria.
There are currently three products available using this technology, two for humans and one for animals. e4life personal is the portable, lightweight, compact version (100 grams x 8.5 cm) which is SAR certified. It is comfortable and safe to wear and is able to inactivate viruses by generating a 'bubble' with a diameter of about three metres. Then there is e4life ambient which is the 'fixed' version to be installed either on ceiling or walls with a range of action covering about 50 square metres.
Lastly there is e4life FARM, the device dedicated to livestock farms and designed to combat animal viral diseases (actually Avian Flu and Swine Flu) which represent a threat to chicken, turkey and pigs.
'This technology marks a breakthrough for applications in high-risk environments, both human and animal, such as farms, where controlling airborne virus transmission is essential, to minimize contagion among the animals themselves and also to reduce the risk of spillover - declares e4life CEO Vincenzo Pompa -. The focus and efficacy of our devices perfectly represent the meaning of what we are doing: it is the starting point of our commitment and it is closely linked to the concept of "One Health", an approach that recognizes and promotes the fundamental interconnection between human, animal and environmental health. Our goal is to revolutionize the biodefense sector through our solutions which allow each individual to enjoy a natural social life, interacting in safe spaces with no concerns or worries'.
Further confirmation of the value and importance of the results achieved by e4life are the numerous examples of recognition it has now received. In actual fact this technology has been subjected to scientific tests and has been validated by the Celio Military Hospital, the independent ViroStatics Institute and two studies published in the Viruses and the European Society of Medicine journals (Source: Esmed.org).
The technology has also been the subject of a test campaign carried out at Milan University's Department of Biomedical and Clinical Sciences. The results confirm those already obtained from previous test campaigns, i.e. a replicable efficacy of close to 90%. The Bio-Medico Campus at the University of Rome has instead collaborated in working on the control and efficacy of this technology.
Furthermore, the JRC–HERA technological prospective study by the European Commission Joint Research Centre includes this technology among those which are currently available that can guarantee an increase in air quality in indoor environments.
The already considerable number of validations has been expanded to include certification obtained from the University of Genoa, which has tested the technology's efficacy of over 90% on influenza and Covid viruses. A final further 'seal of guarantee' comes from an article in the scientific journal Nature Scientific Reports, which describes a study demonstrating the effectiveness of electromagnetic waves in inactivating the avian flu virus.
Moreover, the inactivation systems for respiratory viruses using electromagnetic waves have been included in the UNI/PdR 173-1 Reference Practices for Indoor Sanitization, a document drafted by UNI — the Italian Standardization Body — in collaboration with the National Institute of Health (Istituto Superiore di Sanità). This document sets out the requirements for managing indoor sanitization and the solutions that, even though they are not classified as medical devices, may be used for that purpose.
The e4life devices are currently certified to be marketed in Europe, Australia, Japan, Singapore, Saudi Arabia, UAE, Morocco and Egypt.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Video does not show astronaut exposing 'fake' life in space
"Former Astronaut Karen Nyberg Shows How NASA Fakes Space Flights.." a June 16, 2025 post on X claimed. It shares a video of a woman in front of a space station-like backdrop watching a chip bag float away from her, side-by-side with the same footage being filmed in front of a green screen. A person in a green body suit is manipulating the bag. The video garnered thousands of interactions in posts on X, Threads, Instagram and Facebook. The clip also circulated in posts making similar claims about Nyberg in French, Spanish and Italian. Nyberg is a retired NASA astronaut who completed two spaceflights during her career, including a 166-day stay on the ISS in 2013 (archived here). But she is not the woman in the green screen video. Comments on the post on X included links to previous debunks from USA Today and PolitiFact who named the woman in the video as Paige Windle. In the clip, a person off-camera is heard calling the woman Paige. Windle is the founder of a lifestyle management company and the wife of David Weiss, known online as "Flat Earth Dave," the host of "The Flat Earth Podcast." Contacted by AFP, Weiss confirmed Windle is the one on-camera. "This video never dies. It keeps coming back," Weiss said in a June 17 email. The video was originally posted on Weiss's YouTube channel as part of a series titled "Globebusters," but made no mention of Nyberg (archived here). "Someone took that clip and presented it as Karen Nyberg and it went viral a bunch of times and now it has started again," he said. He said he has repeatedly addressed the false use of the video, sharing with AFP the cover image of a YouTube video he posted in response to the false viral claims (archived here). Astronauts onboard the ISS experience microgravity, causing them and objects to float (archived here). At the altitude of the ISS, gravity is 90 percent of the total gravity one feels on Earth, but an absence of air resistance causes all objects in the ISS to fall at the same rate, producing a weightless appearance. The ISS stays afloat because it moves at a speed that matches the curve of the Earth, causing it to "fall around" the planet while staying at roughly the same altitude. The moon's orbit works in a similar way. NASA uses the ISS in part to study how extended time periods in microgravity and other conditions in space impact the human body as it prepares for future long-term missions in space. On her website, Nyberg features a video she recorded on the ISS where she worked on a quilt (archived here). Unlike in the video filmed in front of the green screen, Nyberg's hair and necklace float throughout the clip due to the microgravity conditions. AFP reached out to Nyberg's representative for comment, but a response was not forthcoming. AFP has previously debunked claims that ISS astronauts faked a video from the station.
Business Wire
2 hours ago
- Business Wire
CCS Presents Four Peer-Reviewed Posters at American Diabetes Association's 85th Scientific Sessions
CHICAGO--(BUSINESS WIRE)-- CCS, a leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions, will present four peer-reviewed posters at the American Diabetes Association's (ADA) 85th Scientific Sessions, which will take place June 20–23 in Chicago. These latest poster presentations illustrate CCS's focus on delivering evidence-based approaches to diabetes care management that ensure patients have the education and coaching they need to thrive and cost-effectively stay adherent while managing their chronic condition. "At CCS, we meet patients where they are — with empathy, education, and evidence-based support..." Share The ADA Scientific Sessions is a globally recognized conference dedicated to advancing the field of diabetes. This annual meeting serves as a critical forum for presenting cutting-edge research, innovation, and new evidence-based approaches to diabetes prevention, management, and care. Presentation Highlights from CCS at the ADA Scientific Sessions CCS's clinical strategy and innovation vice president, Coni Dennis, DNP, RN, and NE-BC, will present findings for all four accepted poster presentations at the ADA's 85th Scientific Sessions, and she shared this insight leading into the event: 'At CCS, we meet patients where they are — with empathy, education, and evidence-based support. These poster presentations reflect our commitment to improving health outcomes for people with diabetes by combining data-driven clinical insight with hands-on, compassionate care.' All poster presentations will take place at the conference on Sunday, June 22, from 12:30–1:30 p.m. CT in West Hall F1. The following are the four specific posters that CCS will be presenting: Presentation Title: Evaluating the Impact of Multichannel Diabetes Care Coaching and Education in Patients New to Continuous Glucose Monitoring Abstract Number: 534 Summary: This study, part of an ongoing randomized control trial (RCT), evaluated whether adults with diabetes newly starting a continuous glucose monitor (CGM) achieve better outcomes when they receive diabetes self-management education and support (DSMES) from a certified diabetes care and education specialist (CDCES), compared to using a CGM alone. Presentation Title: Examining the Impact of Continuous Glucose Monitoring Sourcing in Medicaid Patients — Adherence, Healthcare Costs, and Utilization Abstract Number: 1046 Summary: This study compared healthcare costs and utilization among Medicaid beneficiaries who received CGM supplies through a pharmacy or a durable medical equipment provider. Presentation Title: Healthcare Costs and Utilization Among Patients Eligible for Continuous Glucose Monitors — A Comparison of Users and Nonusers Abstract Number: 1049 Summary: This retrospective cohort study used claims data to compare glycemic control, healthcare utilization, and total cost of care over 12 months among individuals on bolus insulin who used CGMs versus those who did not. It also assessed the incidence of hypoglycemia and diabetic ketoacidosis (DKA). Presentation Title: Evaluating an Evidence-Based Quality Improvement Initiative for Food Insecurity Screening and Referral in Adults with Diabetes Initiating Continuous Glucose Monitor Therapy Abstract Number: 1143 Summary: This study assessed food insecurity (FI) among adults with diabetes initiating CGM therapy, comparing rates to national averages and examining glycemic outcomes between food-insecure and food-secure individuals. These posters will be made available on the American Diabetes Association's website after August 25. About CCS CCS is the strategic partner addressing America's most pressing healthcare challenges through intelligent chronic care management, tackling the $412 billion annual diabetes burden and chronic conditions affecting over 133 million Americans. At the core of CCS's differentiated model is LivingConnected®, a human-led, digitally enabled clinical solution. PropheSee™ — an AI-powered predictive model that identifies nonadherence risk and delivers personalized interventions — is an integral part of this solution, creating a first-of-its-kind platform to improve adherence, enhance clinical outcomes, and help prevent costly hospitalizations. By combining data-driven insights with three decades of industry relationships, CCS is the smart choice for health plans, providers, employers, and manufacturers who believe that value-based care starts by keeping patients healthy and delivers benefits like lower cost of care, improved HEDIS scores, and alleviating provider burnout. CCS's approach extends clinical reach while supporting over 200,000 people nationwide with home-delivered medical supplies and pharmaceuticals annually. Recognized as a Great Place to Work® and with numerous peer-reviewed publications validating our care management approach, CCS is more than a trusted supplier — we're a partner in transforming chronic care delivery. To learn more about how CCS is addressing today's healthcare challenges, visit or connect with us on LinkedIn.
Business Wire
2 hours ago
- Business Wire
OrsoBio to Present Preclinical Data on Mitochondrial Protonophore Portfolio in Models of Obesity at the American Diabetes Association's 85th Scientific Sessions
MENLO PARK, Calif.--(BUSINESS WIRE)--OrsoBio, Inc. ('OrsoBio' or 'the Company'), a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, today announced new preclinical data being presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) being held June 20-23, 2025, in Chicago, Ill. The Company will present three abstracts highlighting the efficacy of its mitochondrial protonophores to induce weight loss and provide glycemic benefits while preserving lean mass in diet-induced obese (DIO) mice. The studies demonstrate the potential of TLC-6740 and TLC-1180—as monotherapy and in combination with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide—for both the induction and maintenance of weight loss following incretin treatment. 'The mechanism of our mitochondrial protonophores to increase energy expenditure complements that of incretins to enhance and sustain weight loss and provide additive metabolic benefits,' said Mani Subramanian, MD, PhD, Chief Executive Officer of OrsoBio. 'These preclinical findings mark an important step in fulfilling our mission to develop innovative, effective, oral therapies for obesity that preserve muscle and support cardiometabolic health.' OrsoBio is advancing a pipeline of novel therapies targeting obesity through mechanistically distinct and complementary approaches. The Company's lead candidates include TLC-6740 and TLC-1180, both mitochondrial protonophores that promote weight loss by increasing energy expenditure. In addition, OrsoBio is developing TLC-3595, a selective inhibitor of acetyl-CoA carboxylase 2 (ACC2), designed to enhance fat oxidation. "GLP-1 receptor agonists have transformed obesity treatment but are limited by gastrointestinal side effects and loss of muscle mass,' said Rob Myers, MD, Chief Medical Officer of OrsoBio. 'Our preclinical data show that our mitochondrial protonophores drive sustained, fat-selective weight loss and metabolic benefits when combined with or sequenced after GLP-1 receptor agonists. These findings support our ongoing Phase 1b study of TLC-6740 in combination with tirzepatide (NCT05822544)." Poster information: Sequential Combination of the Mitochondrial Protonophore TLC-6740 With Semaglutide Normalizes Body Weight and Preserves Lean Mass in DIO Mice Abstract #1687-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study assessed TLC-6740 alone, in combination with low-dose semaglutide (sequential combination), and as maintenance therapy following semaglutide discontinuation in DIO mice. The sequential combination of TLC-6740 with low-dose semaglutide produced superior body weight and fat mass loss, and improved glycemic parameters compared with TLC-6740 alone and high-dose semaglutide. Initiating TLC-6740 after semaglutide discontinuation maintained body weight and fat mass loss, and glycemic benefits. These findings support evaluation of TLC-6740 in combination with incretins in people living with obesity; a 24-week combination study of TLC-6740 with tirzepatide is ongoing (NCT05822544). De Novo or Sequential Combination of the Mitochondrial Protonophore TLC-1180 With Semaglutide Improves Weight Loss and Preserves Lean Mass in DIO Mice Abstract #1694-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study evaluated the effects of TLC-1180 alone, in combination with semaglutide, and as a maintenance treatment following semaglutide discontinuation in DIO mice. As monotherapy, TLC-1180 demonstrated body weight and fat mass loss and preserved lean mass. Body weight and fat mass loss were amplified, and lean mass was preserved with TLC-1180 in combination with semaglutide. These benefits persisted when TLC-1180 was used as a maintenance treatment after semaglutide discontinuation. These data highlight the potential of TLC-1180 as monotherapy, in combination with incretins, or as maintenance therapy post incretin discontinuation in people living with obesity. Novel Combination of a Mitochondrial Protonophore and an Acetyl-CoA Carboxylase 2 (ACC2) Inhibitor Causes Weight Loss and Preserves Lean Mass in Obese Mice Abstract #1686-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study evaluated the effects of the mitochondrial protonophore, TLC-1180, and the ACC2 inhibitor, TLC-3595—as monotherapy and in combination—and semaglutide in DIO mice. TLC-3595 dose dependently reduced body weight, fat mass, and liver biochemistry while preserving lean mass in DIO mice. A combination of TLC-3595 with TLC-1180 had similar weight loss efficacy to semaglutide, but preserved lean mass. Taken together, these data suggest that the novel, all-oral, non-incretin combination of TLC-3595 and TLC-1180 may cause similar weight loss to incretins and may afford additional advantages, including improved weight loss quality and/or tolerability (e.g., reduced incidence of gastrointestinal adverse events). About TLC-6740 TLC-6740 is a novel, oral, liver-targeted mitochondrial protonophore in development for the treatment of obesity and obesity-associated diseases, including diabetes and MASH. Based on active hepatic uptake and mitochondrial protonophore activity, TLC-6740 increases energy expenditure in hepatocytes, and is expected to have broad, systemic metabolic and cardiovascular benefits, including weight loss, improved insulin sensitivity, and as a treatment for MASH, and dyslipidemia. TLC-6740 is currently being evaluated in a Phase 1b clinical trial, as monotherapy and in combination with tirzepatide, in patients living with obesity (NCT05822544). About TLC-1180 TLC-1180 is a novel, potent, long-acting mitochondrial protonophore that has been shown to increase energy expenditure in mice with diet-induced obesity (DIO). In preclinical studies of DIO mice, TLC-1180 induced weight loss, improved glucose control, and enhanced the efficacy of GLP-1 receptor agonists, both as a single agent and in combination with incretins. TLC-1180 is currently completing IND-enabling studies and a first-in-human study is expected to initiate in 2025. About TLC-3595 TLC-3595 is a novel and selective ACC2 inhibitor designed to treat obesity and type 2 diabetes by increasing fatty acid oxidation (FAO), reducing ectopic lipid accumulation, and improving insulin sensitivity in skeletal muscle and liver. The compound may also have potential as a treatment for other conditions characterized by impaired FAO, including heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated steatohepatitis (MASH). About OrsoBio, Inc. OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat obesity and obesity-associated disorders, including type 2 diabetes, MASH, and severe dyslipidemias. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. For more information, please visit
